Elite Pharmaceuticals, Inc. Operating Lease Right-of-Use Assets
Elite Pharmaceuticals, Inc. (ELTP) had Operating Lease Right-of-Use Assets of $1.40 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-13
- 2026-06-30: Operating Lease, Right-of-Use Asset $1.40M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $1.53M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $1.65M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $1.77M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $1.40M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $1.53M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $1.65M 10-Q · filed 2026-02-17 |
| 2025-09-30 | $1.77M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $1.89M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $2.00M 10-K · filed 2026-06-29 |
| 2024-12-31 | $2.11M 10-Q · filed 2025-02-13 |
| 2024-09-30 | $2.09M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $2.22M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $2.36M 10-K · filed 2025-06-30 |
| 2023-12-31 | $26.23K 10-Q · filed 2024-02-14 |
| 2023-09-30 | $1.90K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $7.53K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $13.06K 10-K · filed 2024-07-01 |
| 2022-12-31 | $18.50K 10-Q · filed 2023-02-14 |
| 2022-09-30 | $23.85K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $980.87K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $1.03M 10-K · filed 2023-06-29 |
| 2021-12-31 | $1.08M 10-Q · filed 2022-02-14 |
| 2021-09-30 | $1.14M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $1.20M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $214.67K 10-K · filed 2022-06-29 |
| 2020-12-31 | $212.38K 10-Q · filed 2021-02-16 |
| 2020-09-30 | $263.45K 10-Q · filed 2020-11-16 |
| 2020-06-30 | $313.75K 10-Q · filed 2020-08-14 |
| 2020-03-31 | $363.28K 10-K · filed 2021-06-14 |
| 2019-12-31 | $412.06K 10-Q · filed 2020-02-10 |
| 2019-09-30 | $460.11K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $507.45K 10-Q · filed 2019-08-09 |
| 2019-04-02 | $554.09K 10-Q · filed 2019-08-09 |